Hemo Organic board to weigh fundraise options in 2026

What the company has put on the table

Hemo Organic Limited has scheduled a board meeting for Saturday, October 3, 2026, to consider a proposal to raise funds in one or more tranches. The company said the fundraise may be done through the issue of equity shares and or convertible securities, including convertible warrants. The modes mentioned include preferential allotment and a qualified institutions placement (QIP), subject to statutory and regulatory approvals. In separate disclosures referenced in the provided text, the company has also cited private placement and public issue as possible routes, along with seeking shareholder approval where required. The latest agenda comes amid multiple corporate actions and shareholding changes reported in September 2026.

Board meeting details and the earlier cancellation

As per the provided text, Hemo Organic had also indicated that its Board of Directors would meet on September 23, 2026, to evaluate fund-raising options including equity shares, convertible securities, QIP, preferential allotment, and rights issues. The same text also states that the company cancelled the board meeting scheduled for September 23, 2026. Against that backdrop, the October 3, 2026 meeting becomes the key next event for investors tracking the capital-raising plan. The company has not provided, in the supplied material, the fund size, pricing, or timeline beyond the “one or more tranches” description.

Trading window closure: compliance signal for results season

Hemo Organic said its trading window will remain closed from September 29, 2026. The closure will continue until 48 hours after the declaration of financial results for the quarter and half year ended September 2026. Such trading window restrictions are typically tied to the company’s code of conduct for prevention of insider trading, and are often implemented around periods when unpublished price sensitive information may exist. The disclosure in the provided text does not specify the exact date of the results announcement.

Warrant conversion: 34 lakh shares allotted at ₹12.50

Alongside the proposed fresh fundraise, Hemo Organic has disclosed a completed equity issuance linked to convertible warrants. The company announced the allotment of 34,00,000 fully paid-up equity shares following the conversion of an equal number of convertible warrants. The face value of each equity share is stated as ₹10, and the issue price for the conversion is ₹12.50 per share, which includes a ₹2.50 premium. Based on the figures in the provided text, this transaction raised ₹3.1875 crore.

The disclosures also state that the transaction doubled the company’s paid-up equity share capital, moving from 34,65,900 shares to 68,65,900 shares after allotment. Correspondingly, the paid-up share capital value is described as increasing to about ₹6.86 crore from about ₹3.46 crore, consistent with a ₹10 face value. The company said it would apply for listing of the new shares.

Second tranche receipt from non-promoter allottees

Another regulatory update in the provided text mentions that the Board approved the receipt of a “second tranche” of consideration amounting to ₹2.7625 crore from allottees in the “Non-Promoter” category for convertible warrants. Annexure details cited in the text include Vacro Enterprises Private Limited and Qmin Realities Private Limited. Separately, the text summarises this as Hemo Organic receiving ₹3.19 crore from Vacro and Qmin via warrant conversion, consistent with the total proceeds indicated for the 34,00,000-share allotment.

Shareholding and management changes cited in the disclosures

The supplied material also refers to a non-promoter group led by Ketanaben Jasani and persons acting in concert (PACs) acquiring an additional 11.88% stake. This took their total holding to 18.72%, with the acquisition executed through an off-market purchase on September 24, 2026.

On the governance side, Hemo Organic’s Board appointed Mr. Ayush Dharmendrabhai Jasani as an Additional Director and Chairperson effective September 9, 2026, subject to shareholder approval. The text also mentions the appointment of Avinashsingh Birendrasingh Rajput as Chief Financial Officer. Separately, it records that Yukta Prakash Patel was appointed as Company Secretary and Compliance Officer effective June 27, 2025.

Financial snapshot and market-cap references in the text

The provided text includes a performance datapoint: standalone net sales for March 2026 were ₹0.93 crore, down 61.6% year-on-year. It also states that disclosures “consistently” mention the company’s total equity share capital remained unchanged at 34,65,900 equity shares of face value ₹10 each, which appears to refer to the period before the 34,00,000-share allotment on warrant conversion described elsewhere in the same material.

On valuation, the text contains multiple market-cap references. It states that the market cap of Hemo Organic Ltd (HEMORGANIC) was ₹15.02 crore as of September 28, 2026. Elsewhere in the provided content, “Market Cap” is also shown as ₹7.22 crore and as “₹15 Crs” and “7 Cr”. These figures are presented as-is in the source text and may reflect different timestamps, data sources, or market moves.

Strategic context: chemical manufacturing project near Khambhat

Beyond capital-market actions, the text notes that the company plans a strategic shift by entering the chemical manufacturing space with a new project near Khambhat, Gujarat. The supplied material does not provide project size, capex, timelines, or regulatory clearances, but the mention provides context on why the company may be evaluating additional funding routes.

Key facts at a glance

Market impact: what investors can verify right now

From the information provided, the immediate, measurable impact is the increase in equity base following the warrant conversion allotment. The company’s paid-up shares rising from 34,65,900 to 68,65,900 implies dilution for existing shareholders, while also bringing in ₹3.1875 crore of funds as stated. The upcoming October 3 board meeting is the next formal step that could introduce another round of equity or convertible issuance, depending on the Board’s decision and the approvals it seeks.

The trading window closure beginning September 29, 2026 also signals that financial results are expected, and the closure restricts insiders from trading until 48 hours after results are declared. Investors typically track these dates closely because they align with periods when new financial information may become public.

Why the fundraise decision matters

The company’s repeated references to multiple issuance routes, including preferential allotment and QIP, indicate flexibility in structuring a fundraise based on investor appetite and regulatory requirements. The disclosures already show the company has been using convertible warrants as a financing tool, with conversions leading to fresh equity allotments. The mention of a chemical manufacturing project near Khambhat adds strategic context, as new projects often require incremental capital.

At the same time, the text’s financial datapoint of March 2026 net sales at ₹0.93 crore, down 61.6% year-on-year, underlines why investors will likely watch both the results for the quarter and half-year ended September 2026 and the details of any proposed fundraise.

Conclusion

Hemo Organic’s October 3, 2026 board meeting is set to decide whether the company will pursue another fundraise via equity shares and or convertible securities, after it recently allotted 34,00,000 shares on warrant conversion at ₹12.50 each and raised ₹3.1875 crore. With the trading window shut from September 29, 2026 until after the September 2026 period results are declared, the next set of regulatory filings should clarify the company’s financial position and any further capital-raising steps, including whether shareholder approval will be sought.